Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-10-03
2006-10-03
Lewis, Patrick (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S026200, C536S026230, C536S026260, C514S045000, C514S046000, C514S047000, C514S050000, C514S051000
Reexamination Certificate
active
07115585
ABSTRACT:
The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that has been modified by attaching a degradation resistant substituent on the terminal phosphate of a polyphosphate mononucleotide. By attaching this degradation resistant substituent, the stability from degradation matches or exceeds those of certain dinucleotides.
REFERENCES:
patent: 3321463 (1967-05-01), Moffatt
patent: 5292498 (1994-03-01), Boucher, Jr.
patent: 5628984 (1997-05-01), Boucher, Jr.
patent: 5635160 (1997-06-01), Stutts, III et al.
patent: 5654285 (1997-08-01), Ingall et al.
patent: 5721219 (1998-02-01), Ingall et al.
patent: 5747496 (1998-05-01), Cox et al.
patent: 5837861 (1998-11-01), Pendergast et al.
patent: 5900407 (1999-05-01), Yerxa et al.
patent: 5955447 (1999-09-01), Ingall et al.
patent: 6166022 (2000-12-01), Brown et al.
patent: 6319908 (2001-11-01), Yerxa et al.
patent: 6323187 (2001-11-01), Yerxa et al.
patent: WO 92/17488 (1992-10-01), None
patent: WO 94/18216 (1994-08-01), None
patent: WO 97/03084 (1997-01-01), None
patent: WO 98/28300 (1998-07-01), None
patent: WO 00/33080 (2000-06-01), None
patent: WO 00/34283 (2000-06-01), None
patent: WO 01/19826 (2001-03-01), None
patent: WO 01/36421 (2001-05-01), None
patent: WO 01/39781 (2001-06-01), None
Moffatt et al., “Nucleoside Polyphosphates . . . ”, Journal of the American Chemical Society (1958), 80, 3756-61.
U.S. Appl. No. 09/643,138—Boyer et al.
Abbracchio and Burnstock, “Purinergic Signalling: Pathophysiological Roles,”Jpn J. Pharmacol, 78:113-45 (1998).
Brown, H., et al., “Evidene that UTP and ATP Regulate Phospholipase C through a Common Extracellular 5′- Nucleotide Receptor in Human Airway Epithelial Cells,”Mol. Pharmocol. 40:648-55 (1991).
Drutz, D., et al., “Uridine 5′ Triphosphate (UTP) Regulates Mucociliary Clearance Via Purinergic Receptor Activation,”Drug Dev. Res.37(3):185 (1996).
Gobran, “P2upurinoceptor stimulation of surfactant secretion coupled to phosphatidylcholine hydrolysis in type II cells,”Am. J. Physiol. 267:L625-L633 (1994).
Letham, M., et al., “Nucleotide Regulation of Goblet Cells in Human Airway Epithelial Explants: Normal Exocytosis in Cystic Fibrosis,”Am. J. Respir. Cell Mol. Biol.9:315-22 (1993).
Mason, S., et al. “Regulation of transepithelial ion transport and intracellular calcium by extracellular ATP in human normal and cystic fibrosis airway epithelium,”Br. J. Pharmacol.103:1649-56 (1991).
Schwartz, “Current Concepts in Ophthamology,”N.Engl. J. Med., 290:182-186 (1978).
Brown Edward G.
Crean Christopher S.
Douglass, III James G.
Peterson Ward M.
Shaver Sammy Ray
Howrey LLP
Inspire Pharmaceuticals Inc.
Kung Viola T.
Lewis Patrick
LandOfFree
Compositions for treating epithelial and retinal tissue... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions for treating epithelial and retinal tissue..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for treating epithelial and retinal tissue... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3715468